Just 10–15 years ago, gene therapy was perceived as a technology from the future. Today, it is no longer a theory: there are approved cell and gene therapies in the world, and regulators, manufacturers and healthcare systems are separately building rules for working with this class of products. But it is important to understand the main thing: gene therapy is not a “magical DNA rewriting”, but an expensive, complex and very uneven market with great potential and no less limitations.
The gene therapy market is not just about the drugs themselves. It is a whole system that includes:
That is, we are not talking about one “drug of the future,” but about a separate segment of biopharma, where science, production, ethics, and economics are linked into one very expensive mechanism.
The reason is simple: some gene therapies try to influence not only the symptoms, but also the molecular basis of the disease. That is why the industry is developing especially actively in areas where traditional approaches have been weak or have not provided a long-term effect – for example, in certain rare genetic diseases, some blood diseases, and some oncological or cellular approaches.
But it’s important not to overdo it: not every gene therapy literally “fixes” the root cause. It often involves adding a functional copy of a gene, modifying cells, or some other mechanism to compensate for the impaired function.
If the first wave of gene therapy is the treatment of rare diseases, then the second wave is already entering the zone:
And this is where the topics of telomerase and TERT, which until recently were purely academic, come into play.
There are several real growth drivers in the industry:
The availability of approved cell and gene therapies moves the topic from the category of “promising research” to the category of a real working, albeit narrow, market.
Genome editing, including CRISPR approaches, has expanded the toolbox, but this does not mean an automatic mass transition to the clinic. Between a laboratory breakthrough and routine medical practice, there are often years of testing, safety, manufacturing and regulatory barriers.
CRISPR and gene editing are just part of the puzzle.
The next level is:
Orphan and severe diseases remain the main growth area, as there is a greater willingness to take on expensive and complex solutions than in mainstream diseases. This also explains why the market is growing rapidly in terms of investment but slower in terms of widespread availability.
One reason for the hype around gene therapy is its cost. Some products cost hundreds of thousands or even millions of dollars per course. But the high price is not just a “technology premium.” It is a consequence of complex manufacturing, small patient populations, expensive clinical programs, and stringent quality and logistics requirements. That is why the key question for the market today is not only “does it work?” but also “who will pay for it and how?”
This is where marketing ends and reality begins.
Scaling up cell and gene therapies remains challenging. The challenge is not just in formula, but in consistently releasing a product of consistent quality. The FDA even separately communicates the issue of CMC flexibility for this segment, which in itself shows that the manufacturing part is critical here.
For rare diseases, regulators allow for more flexible approaches, but that doesn’t mean “simplification.” It’s just that the standard evidence model doesn’t always work for very small populations.
The WHO makes a clear distinction between somatic editing, which is not passed on to offspring, and germline editing, where ethical and legal issues are much more acute. This should be made very clear in public communication.
Even if a therapy is clinically successful, it does not mean widespread access. There is a huge gap between approval, payment, reimbursement, administration centers, and the actual patient journey.
The coming years will most likely not bring “mass gene therapy for all.” A more realistic scenario is an expansion of therapies in narrow segments, development of platforms, improvement of production processes, and search for payment models for very expensive courses. That is, the market will grow, but not linearly and not painlessly.
The gene therapy market is moving from “treatment” to controlling cell biology.
And if today it’s about rare diseases,
then tomorrow – about:
➡️ This is where the new zone begins:
генотерапія + теломери + сигнальні молекули
Gene therapy is not the “new oil of medicine” or a magical life-editing. It is one of the most capital-intensive, technologically complex, and promising segments of biopharma. Its strength lies in the ability to influence serious diseases in a new way. Its weakness lies in the cost, complexity of production, ethical boundaries, and the problem of access. That is why it is more honest to talk about gene therapy not as a ready-made revolution, but as a market that has already proven its reality, but has not yet overcome its own barriers.
Gene therapy is gradually moving beyond the “treatment of a specific disease” and into more fundamental processes — aging, cellular stability, and telomere biology.
This means that the next stage of market development is not just new drugs, but cell resource management.
➡️ We will analyze this in detail in the following article:
“Gene therapy, telomeres and tetrapeptides: can cellular aging be controlled?
What are magnesian-organomineral materials, what is their potential for road construction, and why it is not worth promising “minus CO₂” without LCA.
The role of telomeres, telomerase, and gene therapy in controlling cellular aging. A simple explanation of complex biological processes.
How the gene therapy market works, why it is growing, what is holding it back, and why it is one of the most complex segments of modern biopharma
